Aptus Pharma
add_icon

Aptus Pharma

350.00
-0.90
(-0.26%)
Market Cap
240.08 Cr
PE Ratio
-
Volume
4,000.00
Day High - Low
350.90 - 350.00
52W High-Low
364.00 - 80.80
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
240.08 Cr
EPS
6.37
PE Ratio
-
PB Ratio
12.04
Book Value
29.13
EBITDA
4.90
Dividend Yield
0.00 %
Return on Equity
44.50
Debt to Equity
1.79
Forecast For
Actual

Company News

View All News
Caret
positive
Aptus Pharma Limited published newspaper advertisement confirming electronic dispatch of postal ballot notice dated March 24, 2026 for authorized capital increase and 3:2 bonus shares issue with e-voting period from March 27 to April 25, 2026.
positive
Aptus Pharma Limited has scheduled a board meeting for March 24, 2026, to consider increasing authorized share capital and recommending bonus equity shares to shareholders.
positive
Aptus Pharma Limited announces strategic business expansion into Life-Saving Injectables and ICU Care product category, targeting critical care conditions and hospital settings.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,430.40
#1 97,091.60
53.59
#1 24,630.60
14.26
#1 2,203
-61.57
44.18
1,264.80
41,850.30
82.02
15,737.30
23.58
834
-35.40
39.91
1,619.40
33,297.26
64.08
12,042.70
23.73
591
-39.17
40.83
6,944.00
24,437.09
123.78
10,046.60
#1 48.08
251
-125.14
52.62
246.05
15,843.53
31.98
7,932.40
7.48
564
-9.74
53.00
324.55
14,174.87
48.48
5,598.70
14.48
314
-5.15
53.02
845.65
10,728.92
31.20
8,110.20
15.97
363
-39.55
51.39
471.55
9,119.97
55.46
2,451.50
11.53
164
-71.43
53.11
481.40
6,592.82
82.33
2,789.50
1.31
108
-44.50
49.33
750.05
5,150.70
#1 30.84
1,622.70
34.46
213
#1 300.00
46.09
Growth Rate
Revenue Growth
37.43 %
Net Income Growth
287.50 %
Cash Flow Change
15.21 %
ROE
-1.51 %
ROCE
105.69 %
EBITDA Margin (Avg.)
127.53 %

Yearly Financial Results

Annual Financials
2023
2024
2025
TTM
Revenue
14
18
25
0
Expenses
13
16
20
0
EBITDA
1
2
5
0
Operating Profit %
4 %
9 %
20 %
0 %
Depreciation
0
0
0
0
Interest
0
0
1
0
Profit Before Tax
0
1
4
0
Tax
0
0
1
0
Net Profit
0
1
3
0
EPS in ₹
1.30
5.32
6.37
0.00

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
6
10
22
Fixed Assets
1
1
1
Current Assets
6
8
20
Capital Work in Progress
0
0
0
Investments
0
0
0
Other Assets
6
9
21
Total Equity & Liabilities
6
10
22
Current Liabilities
3
4
12
Non Current Liabilities
2
4
3
Total Equity
1
2
7
Reserve & Surplus
1
2
2
Share Capital
0
0
5

Cash Flow

Cash Flow
2023
2024
2025
Net Cash Flow
0
0
4
Investing Activities
-0
-0
-1
Operating Activities
-0
-2
-2
Financing Activities
1
3
7

Share Holding

% Holding
Jun 2025
Sept 2025
Dec 2025
Promoter
72.89 %
72.89 %
72.89 %
FIIs
10.03 %
10.03 %
0.00 %
DIIs
2.80 %
2.80 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
Public / Retail
11.55 %
11.55 %
22.97 %
Others
2.74 %
2.74 %
4.14 %
No of Share Holders
9
9
302

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Nov 2025 129.20 145.50

Announcements

Closure of Trading WindowMar 28, 2026
Newspaper Advertisement Of Notice Of Postal Ballot And E-Voting InformationMar 27, 2026
Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 24/03/2026 Incorporating Additional Details In Compliance With SEBI Circular No. SEBI/HO/CFD/Pod2/CIR/P/0155 Dated November 11 2024.Mar 26, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 26, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On March 24 2026Mar 24, 2026
Closure of Trading WindowMar 17, 2026
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Tuesday March 24 2026Mar 17, 2026
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015: Business ExpansionFeb 26, 2026
Intimation Of Award Received: Recognition As Fastest Growing Ethical Pharma CompanyFeb 24, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2026
Press Release- Aptus Pharma Expands OTC Presence In Gujarat Strengthens Cosmeceutical PortfolioDec 12, 2025
Regulation 30 Disclosure - Entry Into The Urology Therapy SegmentNov 21, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Intimation Of New Product- ENZYKING SYRUPNov 12, 2025
Intimation Of New Product- SHIROVITA HAIR OIL (AYURVEDIC HAIR OIL)Nov 12, 2025
Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 11, 2025
Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Board Meeting Intimation for To Consider And Take On Record Of The Un-Audited Financial Results For The Half Year Ended On 30Th September 2025.Nov 01, 2025
Clarification On Price MovementOct 21, 2025
Clarification sought from Aptus Pharma LtdOct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Closure of Trading WindowOct 01, 2025
Listing of Equity Shares of Aptus Pharma LtdSep 30, 2025

Technical Indicators

RSI(14)
Neutral
71.78
ATR(14)
Less Volatile
9.45
STOCH(9,6)
Neutral
71.55
STOCH RSI(14)
Oversold
12.57
MACD(12,26)
Bullish
0.69
ADX(14)
Very Strong Trend
52.08
UO(9)
Bearish
74.91
ROC(12)
Uptrend And Accelerating
11.57
WillR(14)
Neutral
-20.33